Inactive

NOTICE OF INTENT (NOI) Inova Fairfax Hospital Biorepository Product Service Code (PSC): 6640 NAICS Code: 541380 Place of Performance: Bethesda, MD 20892 USA POTS Number: 25-009982 Description This is ... NOTICE OF INTENT (NOI) Inova Fairfax Hospital Biorepository Product Service Code (PSC): 6640 NAICS Code: 541380 Place of Performance: Bethesda, MD 20892 USA POTS Number: 25-009982 Description This is a Notice of Intent, not a request for quotation. No solicitation will be issued, and no quotations will be requested. The National Institutes of Health (NIH) intends to award a fixed-price purchase order for a biorepository to: Inova Fairfax Hospital, Advanced Lung Disease Clinic 3300 Gallows Road, Fairfax, VA 22042 The establishment of this contract with Inova Fairfax Hospital will provide access to a patient population to develop a biorepository of patients suspected of or diagnosed with Pulmonary Hypertension (PH). The objective is to collect blood samples, demographics, clinical assessments, and outcome data in enrolled subjects. These samples will allow translational research across all the World Health Organization (WHO) PH groups. Scientific Rationale Pulmonary Hypertension (PH) is a multifaceted and progressive condition characterized by elevated pulmonary arterial pressure, which can lead to right heart failure and death if untreated. The World Health Organization (WHO) classifies PH into: • Group 1: Pulmonary arterial hypertension (PAH) due to direct pulmonary vascular injury • Group 2: PH related to left-sided heart failure • Group 3: PH from parenchymal lung disease with hypoxemia • Group 4: PH from chronic thromboembolic disease • Group 5: PH with unclear and/or multifactorial mechanisms In practice, patients with PH are often heterogeneous and present overlapping features that can change over time. Significant overlap between phenotypes makes therapeutic decisions challenging. The data collected will be used to: • Investigate the ability of biomarkers to distinguish between PH groups • Elucidate underlying molecular phenotypes • Predict clinically relevant outcomes • Identify non-invasive biomarkers to track disease progression and therapeutic response Justification for Sole Source Funding for the research to be completed with the patient samples obtained through this contract is from the 2025 Research Award for Staff Clinicians (RASCL) Award to our program. For the initial studies, we need a local PH center of excellence that has an existing affiliation and contracts with our intramural collaborators, the Laboratory of Applied Precision Omics. In order to maintain the integrity of our research plan and adhere to the proposed work that received funding, competition must be limited. Inova Fairfax Hospital is the only local PH center of excellence with this existing affiliation and contractual relationship. This procurement is conducted under FAR 13.106-1(b)(1) (Simplified Acquisition Procedures). For purchases under the Simplified Acquisition Threshold (SAT), contracting officers may limit solicitation to a single source if only one supplier is reasonably available. Consequently, this contract is exempt from FAR Part 6 competition requirements. The total contract value will not exceed the SAT limit of $250,000.00. Submission Instructions Interested parties may express interest and submit capability statements referencing this posting. The Government retains sole discretion to determine whether competition is necessary based on responses received. Capability statements citing this posting number must be submitted electronically to: Office of Purchasing and Contracts Attn: Shasheshe Goolsby, Lead Contract Specialist Email: shasheshe.goolsby@nih.gov By: September 26, 2025, 6:30 AM EST Please note: Only capability statements are requested. This is NOT a solicitation or request for quotations.